Neumora Therapeutics, Total Debt vs. Number Of Employees
| NMRA Stock | 9.77 0.10 1.03% |
For Neumora Therapeutics, profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Neumora Therapeutics, to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Neumora Therapeutics, Common utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Neumora Therapeutics,'s most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Neumora Therapeutics, Common over time as well as its relative position and ranking within its peers.
Neumora |
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neumora Therapeutics,. If investors know Neumora will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neumora Therapeutics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.20) | Return On Assets (0.38) | Return On Equity (0.77) |
The market value of Neumora Therapeutics, is measured differently than its book value, which is the value of Neumora that is recorded on the company's balance sheet. Investors also form their own opinion of Neumora Therapeutics,'s value that differs from its market value or its book value, called intrinsic value, which is Neumora Therapeutics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neumora Therapeutics,'s market value can be influenced by many factors that don't directly affect Neumora Therapeutics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neumora Therapeutics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Neumora Therapeutics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neumora Therapeutics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Neumora Therapeutics, Number Of Employees vs. Total Debt Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Neumora Therapeutics,'s current stock value. Our valuation model uses many indicators to compare Neumora Therapeutics, value to that of its competitors to determine the firm's financial worth. Neumora Therapeutics, Common is rated top company in total debt category among its peers. It also is considered to be number one stock in number of employees category among its peers . The ratio of Total Debt to Number Of Employees for Neumora Therapeutics, Common is about 42,185 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Neumora Therapeutics,'s earnings, one of the primary drivers of an investment's value.Neumora Total Debt vs. Competition
Neumora Therapeutics, Common is rated top company in total debt category among its peers. Total debt of Health Care industry is now estimated at about 3.57 Billion. Neumora Therapeutics, adds roughly 5.23 Million in total debt claiming only tiny portion of equities under Health Care industry.
Neumora Number Of Employees vs. Total Debt
Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Neumora Therapeutics, |
| = | 5.23 M |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
Number of Employees shows the total number of permanent full time and part time employees working for a given company and processed through its payroll.
Neumora Therapeutics, |
| = | 124 |
Employee typically refers to an individual working under a contract of employment, whether oral or written, express or implied, and has recognized his or her rights and duties. Most officers of corporations are included as employees and contractors are generally excluded.
Neumora Number Of Employees vs Competition
Neumora Therapeutics, Common is considered to be number one stock in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 23,487. Neumora Therapeutics, maintains roughly 124 in number of employees contributing less than 1% to equities under Health Care industry.
Neumora Therapeutics, Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Neumora Therapeutics,, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Neumora Therapeutics, will eventually generate negative long term returns. The profitability progress is the general direction of Neumora Therapeutics,'s change in net profit over the period of time. It can combine multiple indicators of Neumora Therapeutics,, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -76 K | -79.8 K | |
| Net Loss | -117.8 M | -123.7 M | |
| Operating Income | -188.2 M | -197.6 M | |
| Net Loss | -235.9 M | -247.7 M | |
| Income Before Tax | -235.7 M | -247.4 M | |
| Total Other Income Expense Net | -47.5 M | -45.1 M | |
| Net Loss | -235.9 M | -224.1 M | |
| Income Tax Expense | 268 K | 281.4 K | |
| Net Interest Income | 16.6 M | 17.4 M | |
| Interest Income | 16.6 M | 17.4 M | |
| Change To Netincome | 20.1 M | 19.1 M | |
| Net Loss | (1.49) | (1.56) | |
| Income Quality | 0.69 | 0.43 | |
| Net Income Per E B T | 0.90 | 0.80 |
Neumora Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Neumora Therapeutics,. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Neumora Therapeutics, position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Neumora Therapeutics,'s important profitability drivers and their relationship over time.
Use Neumora Therapeutics, in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Neumora Therapeutics, position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Neumora Therapeutics, will appreciate offsetting losses from the drop in the long position's value.Neumora Therapeutics, Pair Trading
Neumora Therapeutics, Common Pair Trading Analysis
The ability to find closely correlated positions to Neumora Therapeutics, could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Neumora Therapeutics, when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Neumora Therapeutics, - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Neumora Therapeutics, Common to buy it.
The correlation of Neumora Therapeutics, is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Neumora Therapeutics, moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Neumora Therapeutics, moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Neumora Therapeutics, can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Neumora Therapeutics, position
In addition to having Neumora Therapeutics, in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Cigarettes Thematic Idea Now
Cigarettes
Tobacco makers and distributors across globe. The Cigarettes theme has 47 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Cigarettes Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Correlation Analysis. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
To fully project Neumora Therapeutics,'s future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Neumora Therapeutics, at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Neumora Therapeutics,'s income statement, its balance sheet, and the statement of cash flows.